Mapping the Pathway to Designing Successful Treatments
This executive summary includes evidence on how the right guidance at the right time can help you create more successful treatments.
OptiDose® Design Solution Capabilities Sheet
Summary: OptiDose Design Solution is a comprehensive drug design assessment consisting of a holistic review of the molecule, patient, and market considerations. Led by Catalent’s highly experienced team of scientific advisors, this evaluation assesses key drug design considerations that can help create more successful treatments for all stakeholders.
Use of PBPK Modeling for Predicting and Optimizing Controlled Release Dosage Forms
Summary: Experts will share how dissolution tools and PBPK modeling can help evaluate whether a molecule is suitable for controlled release applications.
Strategies to Optimize the Dosage Form Design Process to Create Better Treatments
Summary: Experts use case studies to demonstrate how the right guidance, at the right time, can help drug developers create better treatments.
Mapping the Pathway to Designing Successful Treatments
Summary: Experts introduce Catalent’s new OptiDose™ Design Solution, an integrated dose form design strategy based on an analyzation of your molecule, patient, and market.
OneXpress™: Phase Appropriate Technology & Expertise from Development to Commercialization
Summary: OneXpress is a single integrated solution that provides the fastest pathway from clinical development to commercial manufacturing. By taking a proactive approach and assessing production considerations early in development, our teams…
Early Phase Solutions
Summary: Explore how you can leverage Catalent’s successful track record optimizing thousands of molecules, deep development expertise and broadest set of superior technologies to…
Patient-Focused Drug Design: Through the Lens of Real-World Case Studies, Clinical Evidence and Advanced Delivery Solutions
Summary: Join this webinar to discover the current state of patient-focused dose design through clinical evidence, real-world case studies and patient preference-driven drug design solutions that can help develop better treatments and successful real-world outcomes.
All Offerings
Summary: Catalyst + Talent. Our name combines these ideas. From drug and biologic development to delivery technologies and supply solutions, we are the catalyst for your…
Designing a Turnkey Orphan Drug Program
Summary: This Endpoints News webinar brings four experts who represent some of the key constituencies when developing a modern orphan program – from early research through approval.
Model to Predict Process Parameters for Scale-Up of Hot Melt Extrusion Process
Summary: Technology transfer and scale-up from a laboratory-scale to commercial-scale HME process require several in-depth empirical studies during product development. Without prior calculations and in-silico scale-up…
Age-Appropriate Formulation Development for Pediatric Trials: Challenges and Considerations
Summary: In this webinar, industry experts discuss the recent advances, challenges and considerations in pediatric drug development. Real-life examples presented by the experts…
Drug Design and the Patient Journey
Summary: Patient-focused drug design can be a key factor in real-world therapeutic outcomes and business success. But if successful treatments should be created with patients in mind…
Catalent: Customizable Innovative Solutions
Summary: Catalent is staying on top of innovation maintaining deep and strategic relationships with our customers and our partners. It is critical for Catalent to understand the…
Catalent: Why Catalent
Summary: Customers work with Catalent because they know that they can come to us and have their most difficult problems solved. They also come to us because there’s no other company out there…
How to Effectively Work with a Development Partner – From a Consultant Standpoint
Summary: Determining a client’s primary goal is critical to guiding them through the development of their asset. Three experienced industry colleagues recently presented on the latest tips…
Behind the Scenes: Catalent IPO on the NYSE
Summary: On July 31, 2014, Catalent officially listed on the NYSE. Take a look behind the scenes at the NYSE on listing and closing bell day.
Catalent in 30 Seconds
Summary: With over 80 years serving the industry, Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products….
Optimal Drug Delivery Technologies. Better Treatments.
Summary: We are your catalyst for creating better treatments. Our deep expertise in drug development, delivery and supply can help improve the bioavailability of your compound, enhance therapeutic profiles…
Catalent Corporate Overview
Summary: Catalent is the global leader in development, delivery, and supply for pharmaceuticals, biologics, and consumer health products. Integrated analytical and clinical supply services support to…
Create Patient-centric Dosage Forms with Catalent
Summary: A short video on Catalent’s expertise and technologies to help achieve target therapeutic profiles and optimize bioavailability, stability and scalability to create patient-centric…
Unlock Your Molecules Potential with Catalent
Summary: Your molecule has so much potential, we share the passion to unlock it through extensive expertise and superior formulation technologies. Learn how we have optimized thousands…
Bring Pharma, Biopharma and Consumer Health Products to Market with Catalent
Summary: A short video on how Catalent can help you develop, deliver, supply better treatments. Whether it is Pharmaceuticals, Biopharmaceuticals, Over-the-Counter, Nutritionals or Beauty Care and Cosmetics, we can…
OptiForm® Solution Suite – Fast Track Early Development | Catalent in 90 Seconds
Summary: Learn about a Fast, Flexible and Fact-based path for your molecule to progress from late-stage discovery to phase I.
Join Catalent in Bringing Better Treatments to Patients Worldwide
Summary: At Catalent, you will have numerous opportunities to take personal initiative, thrive in a dynamic environment, and make an impact. Allow our employees to tell you about life at Catalent and…
Meet Aileen B. – GOLD Graduate
Summary: The Catalent GOLD (Global Organization Leadership Development) Program is a two-year rotational development opportunity…
Career Development at Catalent
Summary: Catalent offers employees numerous opportunities for development and career progression. Hear more about what our team has to say about how Catalent supports their…
Product Development Careers at Catalent
Summary: Members of our product development eam gain unparalleled experience working on several products using multiple technologies. Hear what it’s like to work…
Why Do New Therapies Succeed Or Fail In The Marketplace?
How can decisions made during the preclinical phase of drug development increase the chances of a product’s eventual success in a difficult marketplace?
Better Treatments By Design
To be successful, new treatments require real-world outcomes for you, your stakeholders, and most importantly the patients.
Particle Size Reduction
Characterization of the micronized drug is important to understand its bulk properties and design downstream processes and manufacturing approaches.
Catalent Spray Drying Technology
A holistic approach to the development and manufacture spray dried dispersions.
Considering Patient’s Voice in Drug Design
Strategies on incorporating patient opinion into early drug design and boost patient adherence.
Patient-centric Dose Design
Avoid some of the limitations of conventional tablet dose forms & more.
The Medicine Maker – Finding Optimal Form
Increase chances of success in drug development by focusing on API optimization from the start.
Softgel Capsules Low Batch Size Optimize in cGMP Labs
Handle small amounts of API or formulation at the early stages of development.
Optimization of Type I & II Lipid Based Drug Delivery System
Limit individual variability of type I & II systems with adequate choice of composition.
The Versatility of Softgel Technology
Optimize manufacturing parameters like lower processing temperature & thinner softgel shell.
Lipid-Based Delivery of Peptide Therapeutics
An explanation of OptiGel Bio™ technology as a delivery tool for macromolecule NCE candidates.
Conversion from LFHS to RP Scherer Softgel Capsules
RP Scherer Technology can improve timelines and commercialization potential.